Methodological considerations in cost of illness studies on Alzheimer disease

Health Economics Review

Volumn 2, Issue 1, 2012, Pages 1-12

  Costa, Nagede ^a,b   Derumeaux, Helene ^a   Rapp, Thomas ^d   Garnault, Valérie ^a   Ferlicoq, Laura ^a   Gillette, Sophie ^b,c,d   Andrieu, Sandrine ^a,b,c   Vellas, Bruno ^a,b,c   Lamure, Michel ^e   Grand, Alain ^a,b,c   Molinier, Laurent ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c Faculté de Médecine Centre Hospitalo universitaire   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

Alzheimer disease; Cost study; Dementia; Economic; Evaluation; Review

Indexed keywords

ALZHEIMER DISEASE; COST OF ILLNESS; DATA ANALYSIS; EVALUATION RESEARCH; HEALTH CARE MANAGEMENT; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLISHING; QUESTIONNAIRE; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84971255228     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-2-18     Document Type: Review

References (53)

1. Byford S, Torgerson DJ, Raftery J: Cost of illness studies. BMJ 2000, 320:1335.
2. Koopmanschap MA: Cost of illness studies: Useful for health policy? PharmacoEconomics 1998, 14(2):143-148.
3. Hogdson TA: Annual costs of illness versus Lifetime costs of illness and implications of structural change. Drug Inf J 1988, 22:323-341.
4. Alzheimer's Association Reports: 2011 Alzheimer's disease facts and figures. W V Med J 2011, 107(3):82-83.
5. Wimo A, Prince M: World Alzheimer Report 2011, The global Economic Impact of Dementia. Alzheimer Disease Int 2010, 1-52.
6. O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S: Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. Journal Am Gerriatr soc 1999, 47(5):570-578.
7. Hill JW, Futterman R, Mastey V, Fillit H: The effect of donepezil therapy on health costs in a Medicare managed plan. Manag Care Interface 2002, 15(3):63-70.
8. Jönsson L, Wimo A: The cost of dementia in Europe: a review of the evidence, and methodological considerations. PharmacoEconomics 2009, 27(5):391-403.
9. Mauskopf J, Mucha L: A review of the methods used to estimate the cost of Alzheimer's disease in the United States. Am J Alzheimers Dis Other Demen 2011, 26(4):298-309.
10. McDaid D: Estimating the costs of informal care for people with Alzheimer's disease: methodological and practical challenges. Int J Geriatr Psychiatry 2001, 16(4):400-405.
11. Drummond MF: Methods for the economic evaluation of health care programmes. 3rd edition. Oxford: Oxford University Press; 2005.
12. Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Soulié M, Daurès JP, Grosclaude P: Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health 2008, 11(5):878-885.
13. Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J: Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 2006, 26;67(12):2186-2191.
14. Coduras A, Rabasa I, Frank A, Bermejo-Pareja F, López-Pousa S, López-Arrieta JM, Del Llano J, León T, Rejas J: Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. J Alzheimers Dis 2010, 19(2):601-615.
15. Rigaud AS, Fagnani F, Bayle C, Latour F, Traykov L, Forette F: Patients with Alzheimer's disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neuro 2003, 16(3):140-145.
16. Kronborg Andersen C, Søgaard J, Hansen E, Kragh-Sørensen A, Hastrup L, Andersen J, Andersen K, Lolk A, Nielsen H, Kragh-Sørensen P: The cost of dementia in Denmark: the Odense Study. Dement Geriatr Cogn Disord 1999, 10(4):295-304.
17. Cavallo MC, Fattore G: The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alzheimer Dis Assoc Disord 1997, 11(4):184-190.
18. Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L: Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res 2010, 7(4):358-367.
19. Kiencke P, Dietmar D, Grimm C, Rychlik R: Direct costs of Alzheimer disease in Germany. Eur J Health Econ 2011, 12:533-539.
20. Leon J, Neumann PJ: The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care 1999, 5(7):867-877.
21. Hay JW, Ernst RL: The economic costs of Alzheimer's disease. Am J Public Health 1987, 77(9):1169-1175.
22. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, Segura E: The economic burden of Alzheimer's disease care. Health Aff 1993, 12(2):164-176.
23. Leon J, Cheng CK, Neumann PJ: Alzheimer's disease care: costs and potential savings. Health Aff 1998, 17(6):206-216.
24. Ostbye T, Crosse E: Net economic costs of dementia in Canada. CMAJ 1994, 15;151(10):1457-1464.
25. Zencir M, Kuzu N, Beşer NG, Ergin A, Catak B, Sahiner T: Cost of Alzheimer's disease in a developing country setting. Int J Geriatr Psychiatry 2005, 20 (7):616-622.
26. Wang G, Cheng Q, Zhang S, Bai L, Zeng J, Cui PJ, Zhang T, Sun ZK, Ren RJ, Deng YL, Xu W, Wang Y, Chen SD: Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimers Dis 2008, 15(1):109-115.
27. Suh GH, Knapp M, Kang CJ: The economic costs of dementia in Korea, 2002. Int J Geriatr Psychiatry 2006, 21(8):722-728.
28. Beeri MS, Werner P, Adar Z, Davidson M, Noy S: Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord 2002, 16(2):73-80.
29. Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano FE, Sarasola D, Lon L: Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr 2007, 19(4):705-718.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
31. American Psychiatric Association: Diagnostic and Statistical Manual of Mental disorders. 4th editionWashington DC: American Psychiatric Association; 2000.
32. Quentin W, Riedel-Heller S, Luppa M, Rudolph A, König HH: Cost of illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psyciatra Scandinavia 2010, 121:243-259.
33. Small GW, McDonnell DD, Brooks RL, Papadopoulos G: The impact of symptom severity on the cost of Alzheimer disease. Journal American Geriatric society 2002, 50(2):321-327.
34. Mauskopf J, Racketa J, Sherrill E: Alzheimer's disease: the strength of association of costs with different measures of disease severity. J Nutr Health Aging 2010, 14(8):655-663.
35. Herman N, Tam DY, Balshaw R, Sambrook R, Lesnikova N, Lanctôt KL: Canadian Outcomes Study in Dementia [COSID] Investigators, The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada. Can J Psychiatry 2010, 55(12):768-775.
36. Morris JC: The Clinical Dementia Rating [CDR]: current version and scoring rules. Neurology 1983, 43:2412-2414.
37. Crum RM, Anthony JC, Bassett SS, Folstein MF: Population-based norms for the mini-mental state examination by age and educational level. JAMA 1993, 269:2386-2389.
38. Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, Stern Y: Longitudinal study of effects on patient characteristics on direct costs in Alzheimer disease. Neurology 2006, 67(6):998-1005.
39. Tarricone R: Cost of illness analysis. What room in health economics. Health Policy 2006, 77:51-63.
40. Koopmanschap MA, Rutten FF: Indirect costs in economic studies: confronting the confusion. PharmacoEconomics 1993, 4:446-454.
41. Koopmanschap MA, van Ineveld BM: Towards a new approach for estimating costs of disease. Soc Sci Med 1992, 34(9):1005-1010.
42. Hogdson TA, Meiners MR: Cost of illness methodology a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982, 60(3):429-462.
43. Van der Berg B, Brouwer W, Van Exel J, Koopmanschap M, Van den Bos GAM, Rutten F: Economic valuation of informal care: lessons from the application of the opportunity costs and proxy goods methods. Soc Sci Med 2006, 62:835-845.
44. Koopmanschap MA, Van Exel JN, Van den Berg B, Brouwer WB: An overwiew of methods and application to value informal care in economic evaluation of healthcare. PharmacoEconomics 2008, 26(4):269-280.
45. Gold MR, Russel LB, Siegel JE, Daniels N, Weinstein MC: Cost effectiveness in Health and Medicine. JAMA 1996, 276(14):1172-1177.
46. Agro KE, Bradley CA, Mittmann N, et al: Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature. Pharmacoeconomics 1997, 11:75-88.
47. Wiseman V, Mooney G: Burden of illness estimates for priority setting: a debate revisited. Health Policy 1998, 43:243-251.
48. Wimo A, Nordberg G, Jansson W, Grafström M: Assessment of informal services to demented people with the RUD instrument. Int J Geriatr Psychiatry 2000, 15(10):969-971.
49. Davis KL, Marin DB, Kane R, Patrick D, Peskind ER, Raskind MA, Puder KL: The Caregiver Activity Survey [CAS]: development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 1997, 12(10):978-988.
50. Clipp EC, Moore MJ: Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995, 58(2):228-236.
51. Segel JE: Cost-of-Illness studies-A primer, RTI -UNC Center of Excellence in Health Promotion Economics. RTI international. 2006:1-39. http://www.rti. org/pubs/coi_primer.pdf
52. World Bank: World Bank -list economies.County and lending groups. 2011. http://data.worldbank.org/about/country_classifications/country_and_lendinggroups#Upper_middle_income 1
53. Schreyer P, Koechlin F: Purchasing power parities: measurement and uses. Statistics breaf. OECD Statistics brief 2002, 3:1-8.